Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.37 |
| ▸ | CES1 | P23141 | 3/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6992716 | 0.81 | ALB (0.41) | CES2CES1ALBALDH1A1TSHR | |
| SCHEMBL8979738 | 0.77 | CYP3A4 (0.38) | PARP1ALDH1A1POLBCYP3A4MAPT | |
| SCHEMBL10482945 | 0.77 | KDM4E (0.45) | PARP1ALDH1A1POLBCYP3A4MAPT | |
| SCHEMBL11516367 | 0.77 | KDM4E (0.45) | PARP1ALDH1A1POLBCYP3A4MAPT | |
| SCHEMBL10822473 | 0.75 | PARP1 (0.35) | PARP1ALDH1A1POLBCYP3A4MAPT | |
| SCHEMBL9712668 | 0.75 | ALDH1A1 (0.46) | CES2CES1ALDH1A1MAPTTSHR | |
| SCHEMBL18706241 | 0.75 | GAA (0.52) | CES2CES1ALDH1A1MAPTTDP1 | |
| SCHEMBL17977340 | 0.75 | MAOB (0.38) | PARP1ALDH1A1POLBTDP1L3MBTL1 | |
| SCHEMBL27579614 | 0.75 | ALDH1A1 (0.41) | ALDH1A1MAPTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL18705835 | 0.75 | POLB (0.39) | CES2CES1ALDH1A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11845748-B2 | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-19 | — | — | US | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| WO-2009106565-A1 | AGONISTS OF GPR119 | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | claimed |
| WO-2009106561-A1 | PYRAZINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | claimed |
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | claimed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| US-7226926-B2 | 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2007-06-05 | — | — | US | claimed |
| EP-1511748-B1 | 8-FLUORIMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-08-09 | — | — | EP | claimed |
| US-11845748-B2 | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-19 | — | — | US | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
| US-7226926-B2 | 8-fluoroimidazo 1,2-a pyridine derivatives as ligands for GABA receptors | MERCK SHARP & DOHME LTD. (GB) | 2007-06-05 | — | — | US | disclosed |
| EP-1511748-B1 | 8-FLUORIMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | MERCK SHARP & DOHME (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-20060052385-A1 | 8-Fluoroimidazo 1,2-a pyridine derivatives as ligands for gaba receptors | MERCK SHARP & DOHME LTD. (GB) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | CES2 566/4885CES1 239/4885PARP10 348/4885 |
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | CES2 1551/4885CES1 1330/4885PARP10 3610/4885 |
| US-20060052385-A1 | 8-Fluoroimidazo 1,2-a pyridine derivatives as ligands for gaba receptors | GABRA3, GABRA2, GABRA5 | CES2 1066/4885CES1 833/4885PARP10 3410/4885 |
| US-11845748-B2 | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors | F2, F11, KLKB1 | CES2 3769/4885CES1 1244/4885PARP10 532/4885 |
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | CES2 1253/4885CES1 1064/4885PARP10 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.